

Title (en)
GACYCLIDINE FORMULATIONS

Title (de)
GACYCLIDINFORMULIERUNGEN

Title (fr)
FORMULATIONS DE GACYCLIDINE

Publication
EP 2306839 A4 20110817 (EN)

Application
EP 09767730 A 20090618

Priority
• US 2009047801 W 20090618
• US 7413408 P 20080619

Abstract (en)
[origin: WO2009155421A1] Colloidal suspensions comprising gacyclidine and squalene. Squalene binds gacyclidine much more tightly than other drug carriers, such as polylactic glycolic acid. Including squalene in the particulate phase sequesters gacyclidine and provides superior stability at room or body temperature.

IPC 8 full level
A61K 31/453 (2006.01); **A61K 9/00** (2006.01); **A61K 9/107** (2006.01); **A61K 9/51** (2006.01); **A61K 31/13** (2006.01); **A61K 31/135** (2006.01); **A61K 31/445** (2006.01); **A61K 31/451** (2006.01); **A61P 25/00** (2006.01)

CPC (source: EP)
A61K 9/0024 (2013.01); **A61K 9/0046** (2013.01); **A61K 9/0048** (2013.01); **A61K 9/0097** (2013.01); **A61K 9/1075** (2013.01); **A61K 31/137** (2013.01); **A61K 31/4535** (2013.01); **A61P 25/00** (2017.12)

Citation (search report)
• [X] CHUNG H ET AL: "Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 71, no. 3, 28 April 2001 (2001-04-28), pages 339 - 350, XP004234531, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(00)00363-1
• See references of WO 2009155421A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2009155421 A1 20091223; EP 2306839 A1 20110413; EP 2306839 A4 20110817

DOCDB simple family (application)
US 2009047801 W 20090618; EP 09767730 A 20090618